Skip to main content

Table 5 Effects of Tat and morphine on levels of eCB and other lipid signaling molecules (pg/mg) in the striatum and spinal cord of Tat transgenic mice that were not significantly altered by Tat and/or morphine for any of the two CNS regions

From: Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids

CNS region Lipids Genotype Repeated saline Repeated morphine Genotype effect Drug effect Genotype x drug
pg/mg   mean ± SEM mean ± SEM F1, 13 p F1, 13 p F1, 13 p
Striatum 2-AG Tat(−) 11879.7 ± 1270.52 15441.7 ± 2440.16 < 1.0 0.93 2.1 0.17 < 1.0 0.52
Tat(+) 13140.9 ± 2086.96 14476.7 ± 1229.29
AEA Tat(−) 8.4 ± 0.52 9.1 ± 1.87 2.3 0.15 < 1.0 0.47 2.3 0.15
Tat(+) 8.4 ± 1.08 6.4 ± 0.33
NAGly Tat(−) 16.0 ± 1.18 17.0 ± 1.26 < 1.0 0.47 1.0 0.33 < 1.0 0.85
Tat(+) 16.7 ± 1.55 18.10 ± 0.62
POEA Tat(−) 4.9 ± 0.34 5.9 ± 0.93 1.1 0.31 < 1.0 0.36 1.5 0.24
Tat(+) 5.0 ± 0.23 4.8 ± 0.39
LEA Tat(−) 6.0 ± 0.74 7.9 ± 1.71 < 1.0 0.46 < 1.0 0.96 3.2 0.10
Tat(+) 7.1 ± 1.33 5.2 ± 0.67
DEA Tat(−) 2.8 ± 0.09 3.6 ± 0.91 < 1.0 0.39 1.1 0.32 1.7 0.22
Tat(+) 2.9 ± 0.20 2.8 ± 0.16
DHEa Tat(−) 16.1 ± 0.64 18.1 ± 4.25 < 1.0 0.66 < 1.0 0.58 2.9 0.11
Tat(+) 18.4 ± 1.99 14.3 ± 0.61
Spinal cord 2-AG Tat(−) 11168.1 ± 1849.25 13770.4 ± 4148.01 1.4 0.26 1.4 0.26 < 1.0 0.90
Tat(+) 9033.6 ± 993.83 11126.1 ± 1239.95
AEA Tat(−) 5.8 ± 0.79 5.7 ± 2.03 < 1.0 0.77 < 1.0 0.60 < 1.0 0.55
Tat(+) 5.3 ± 0.48 7.1 ± 1.98
NAGly Tat(−) 22.8 ± 2.07 22.3 ± 4.38 < 1.0 0.43 < 1.0 0.74 < 1.0 0.56
Tat(+) 19.6 ± 1.81 21.7 ± 1.19
POEA Tat(−) 8.7 ± 3.12 4.9 ± 0.58 < 1.0 0.83 < 1.0 0.71 < 1.0 0.38
Tat(+) 6.7 ± 2.02 8.3 ± 3.38
LEA Tat(−) 10.6 ± 4.75 5.7 ± 1.40 < 1.0 0.66 < 1.0 0.78 < 1.0 0.52
Tat(+) 9.5 ± 3.85 11.4 ± 6.26
DEA Tat(−) 3.9 ± 0.30 3.8 ± 1.19 < 1.0 0.82 < 1.0 0.37 1.1 0.32
Tat(+) 3.2 ± 0.42 4.3 ± 0.57
DHEa Tat(−) 15.8 ± 0.55 18.4 ± 6.49 < 1.0 0.61 1.5 0.24 < 1.0 0.48
Tat(+) 14.7 ± 1.02 24.9 ± 7.59
  1. Levels of eCB and non-eCB lipids in the striatum and spinal cord of repeated (8-day) saline- or morphine-treated Tat(−) and Tat(+) mice were not significantly affected by Tat and/or morphine for any of the two CNS regions. Data are expressed as mean ± SEM in pg/mg. Two-way ANOVAs for each CNS region were conducted with genotype and drug as between-subjects factors. F values and p values are presented from ANOVA results. n = 3–5 mice per group. All significant effects are represented in Fig. 7